Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2017-12-08 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
2017年第七次临时股东大会的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the convening, attendance, voting procedures, and results of a specific shareholders' meeting (the 2017 seventh extraordinary general meeting) of Kunming Pharmaceutical Group Co., Ltd. It details the legality and validity of the meeting and resolutions passed. This is not a full report like an Annual Report or Interim Report, nor is it a voting result announcement or proxy solicitation. It is a legal opinion related to a shareholders' meeting, which does not fit into categories like MANG, DVA, or PSI. Given the nature of the document as a legal opinion on the shareholders' meeting, it best fits under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or compliance documents that do not fit other categories.
2017-12-08 Chinese
北京德恒（昆明）律师事务所关于公司股权激励计划首次授予事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the 2017 restricted stock incentive plan's initial grant for Kunming Pharmaceutical Group Co., Ltd. It discusses the approval, authorization, adjustments, grant date, and conditions of the stock incentive plan. The document is a legal opinion letter, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or management discussion but provides legal evaluation and compliance confirmation related to a stock incentive plan. This type of document fits best under the category of Regulatory Filings (RNS) as it is a legal compliance document related to corporate governance and stock incentive plans, not a direct financial report or announcement of voting results or capital changes.
2017-12-08 Chinese
关于杨兆祥先生辞去副总裁职务的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company's vice president, specifically Mr. Yang Zhaoxiang, from his position. It includes details about the resignation date and expresses gratitude for his contributions. There is no financial data, no mention of financial results, no regulatory filings, or any other report types. This fits the category of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2017-12-08 Chinese
关于为全资子公司昆明中药厂有限公司提供5,000万元信用担保的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding providing a 50 million RMB credit guarantee for its wholly-owned subsidiary. It details the guarantee amount, the subsidiary's financial status, the purpose of the guarantee, and board approval. There is no financial statement or comprehensive report content, but rather a disclosure of a specific financing-related event. This fits the category of Capital/Financing Update (CAP), as it concerns a financing activity (credit guarantee) and related board approval. The document length is short and focused on this announcement, not a full report or audit.
2017-12-08 Chinese
上海荣正投资咨询有限公司关于公司2017年限制性股票激励计划授予事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an independent financial advisor report regarding the 2017 restricted stock incentive plan grant for Kunming Pharmaceutical Group Co., Ltd. It includes detailed explanations of the stock incentive plan, approval procedures, grant conditions, impact on financials, and advisor opinions. The document is 9020 characters long, contains substantive financial and operational analysis related to a stock incentive plan, and is not merely an announcement or certification. It is not an annual or quarterly report, nor a regulatory filing or announcement. The content fits the category of a detailed advisory report on a capital/financing activity related to stock incentives and equity grants. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2017-12-08 Chinese
独立董事关于2017年限制性股权激励计划调整事项及所涉限制性股票授予事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on the adjustment and granting of restricted stock under the 2017 restricted stock incentive plan of Kunming Pharmaceutical Group Co., Ltd. It references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange listing rules, and discusses compliance and approval of stock incentive plan adjustments and grants. The document is a formal opinion related to a stock incentive plan, not a full financial report, earnings release, or management discussion. It is not a proxy solicitation or voting result announcement, but rather an independent directors' statement on a specific corporate governance matter related to equity incentives. This fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and independent opinion rather than a full report or announcement of voting results.
2017-12-08 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.